EMPA-REG OUTCOME trial of Jardiance (empagliflozin) shows reduced risk of CV death in type 2 diabetes- Boehringer

New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance (empagliflozin), from Boehringer, consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. The findings are part of the landmark EMPA-REG OUTCOME trial, which is the first trial of a diabetes medication to show a reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

For this post hoc analysis, trial participants were grouped based on type of cardiovascular disease at baseline, which included history of heart attack, stroke, heart failure, atrial fibrillation and existing peripheral artery disease. Lower rates of cardiovascular death were seen in the Jardiance group independent of cardiovascular disease type. Observed adverse events were consistent with the known safety profile of Jardiance.